Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 18/20 | 0.61 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.61 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.61 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.61 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540837 | 0.84 | PARP10 (0.64) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL2628977 | 0.80 | CA1 (0.56) | PARP10PARP15ALDH1A1KMT2ACA1 | |
| SCHEMBL12565754 | 0.78 | MAPT (0.61) | ALDH1A1KMT2A | |
| SCHEMBL17480694 | 0.78 | ALDH1A1 (0.41) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL14477632 | 0.78 | MEN1 (0.33) | KMT2ACA1CA2 | |
| SCHEMBL3034248 | 0.78 | PARP10 (0.62) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL3137816 | 0.77 | PARP10 (1.00) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| Terephthalamide SCHEMBL23774 | 0.75 | PARP1 (0.71) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL8401760 | 0.75 | ELANE (0.58) | ALDH1A1KMT2A | |
| SCHEMBL7604825 | 0.75 | CA1 (0.64) | ALDH1A1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-9181247-B2 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20150105401-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER (US) | 2015-04-16 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140058106-A1 | SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-02-27 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8569331-B2 | Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds | ARQULE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | ARQULE, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110054175-A1 | SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | PARP10 3928/4885PARP15 3382/4885PARP4 4054/4885 |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | PARP10 3417/4885PARP15 4307/4885PARP4 3810/4885 |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | PARP10 637/4885PARP15 731/4885PARP4 697/4885 |
| US-20140058106-A1 | SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS | PFAS, ODC1, AOC1 | PARP10 2069/4885PARP15 1994/4885PARP4 2297/4885 |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | PARP10 1436/4885PARP15 1833/4885PARP4 1186/4885 |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | BRD4, BRPF3, BRD3 | PARP10 1029/4885PARP15 266/4885PARP4 767/4885 |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | PARP10 3928/4885PARP15 3382/4885PARP4 4054/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | PARP10 3928/4885PARP15 3382/4885PARP4 4054/4885 |
| US-20150105401-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | PARP10 637/4885PARP15 731/4885PARP4 697/4885 |
| US-20110054175-A1 | SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS | PFAS, ODC1, AOC1 | PARP10 2069/4885PARP15 1994/4885PARP4 2297/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | PARP10 723/4885PARP15 664/4885PARP4 843/4885 |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | PARP10 637/4885PARP15 731/4885PARP4 697/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | PARP10 637/4885PARP15 731/4885PARP4 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.